TF0023 / Techfields - LARVOL DELTA

A Study to Evaluate the Efficacy and Safety of TF0023 Spray on Subjects With Ischemic Strokes (clinicaltrials.gov) - P2 | N=225 | Suspended | Sponsor: Techfields Inc | Trial completion date: Dec 2022 ➔ Dec 2024 | Trial primary completion date: Oct 2022 ➔ Oct 2024

Trial completion date • Trial primary completion date • Cardiovascular • Ischemic stroke

Evaluate the Efficacy and Safety of TF0023 in Treatments for COVID-19 in Hospitalized Adults (clinicaltrials.gov) - P2 | N=19 | Terminated | Sponsor: Techfields Inc | N=400 ➔ 19 | Trial completion date: Jun 2023 ➔ Mar 2023 | Recruiting ➔ Terminated; Low patient accrual.

Enrollment change • Trial completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease • Pneumonia

A Phase 2 Study to Evaluate the Efficacy and Safety of TF0023 compared to Placebo in Treatments for COVID-19 in Hospitalized Adults Estudio de fase 2 para evaluar la eficacia y seguridad de TF0023 frente a placebo en el tratamiento de la COVID-19 en adultos hospitalizados (clinicaltrialsregister.eu) - P2 | N=400 | Ongoing | Sponsor: Techfields Inc.

New P2 trial • Infectious Disease • Novel Coronavirus Disease

A Study to Evaluate the Efficacy and Safety of TF0023 Spray on Subjects With Ischemic Strokes (clinicaltrials.gov) - P2 | N=225 | Suspended | Sponsor: Techfields Inc | Recruiting ➔ Suspended

Trial suspension • Cardiovascular • Ischemic stroke

Evaluate the Efficacy and Safety of TF0023 in Treatments for COVID-19 in Hospitalized Adults (clinicaltrials.gov) - P2 | N=400 | Recruiting | Sponsor: Techfields Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Pneumonia